ClinicalTrials.gg
CompletedNCT01752322Updated Jul 6, 2016

Efficacy and Tolerability of Lidocaine Plaster for Treatment of Long-term Local Nerve Pain

A Phase 3 interventional study of Lidocaine 5% medicated plaster and Placebo plaster in Pain, Chronic Pain and Neuropathic Pain, sponsored by Grünenthal GmbH. Completed at 42 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-06.

Sponsored by Grünenthal GmbH · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
444
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 204 studies testing lidocaine in Pain — 19 open to participants now, 19 under way, 1 of them phase 3. Lidocaine · Pain.

Enrollment
5th of 203
444 · median 66
Started
2012
with 6 others
Phase 3
22 of 204
none open now
Registered
74th of 204
by date

Among the 204 studies testing lidocaine in Pain, this one is the 5th largest by enrollment of the 203 interventional ones that give a count, is one of 7 that started in 2012, is one of 22 in phase 3, and was the 74th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

19 of the 204 studies testing lidocaine in Pain are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About lidocaine

Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 204 studies testing lidocaine in Pain, or all of them as a file.
02

Study summary

The purpose of this trial is to investigate the efficacy and safety of lidocaine 5% medicated plaster in localized chronic post-operative neuropathic pain in comparison to placebo plaster.

03

Conditions studied

  • Pain
  • Chronic Pain
  • Neuropathic Pain
  • Postoperative Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged 18 years or older.
  • Subjects suffering from moderate to severe localized chronic PoNP (post operative neuropathic pain) pain following surgery (e.g., thoracotomy, total/partial knee replacement, cholecystectomy, mastectomy, inguinal hernia repair, varicose vein stripping).
  • Localized PoNP present for at least 3 months.
  • Size of the affected painful skin area is not larger than the size of 3 plasters.
  • Intact skin besides the scar of surgery in the area of plasters application
  • Baseline average pain intensity of 4 or greater on the 11 point pain intensity Numeric Rating Scale.

Exclusion criteria

Exclusion Criteria:

  • Participation in another trial (with medicine or a device under investigation) in parallel or less than 30 days prior to enrollment in this trial.
  • Previous enrollment in this trial.
  • History of dependency or active drug abuse (alcohol, medication) during the 1 year prior to enrollment.
  • Evidence or history (during the 3 years prior to enrollment) of neurotic personality or psychiatric illness that in the investigator's opinion may affect efficacy or safety assessments or may compromise the subjects safety during trial participation.
  • Pregnant or breastfeeding women or women of who are sexually active without satisfactory .
  • Any surgery performed in the 3 months prior to enrollment, which may affect efficacy or safety assessment.
  • Any surgery scheduled or expected during the trial.
  • disease (e.g., acquired immunodeficiency syndrome) or condition that may affect efficacy or safety assessments, or any other reason which, in investigator's opinion, may preclude the subject's participation in the trial.
  • History of (with the exception of neoplasia related to the trial indication) within 2 years prior to enrollment.
  • Subject with PoNP related to a surgery due to neoplasia: suspected residual neoplasia or .
  • Pending litigation due to chronic pain or disability.
  • Total anesthesia in the cutaneous area neurologically related to the location of the surgical intervention.
  • to the lidocaine 5% medicated plaster, its , or anesthetics of the amide type.
  • Any former use of topical lidocaine in the area of localized chronic PoNP.
  • Severe renal, hepatic or heart disorder.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
444 participants (actual)

Study arms

  • Experimental
    Lidocaine plaster

    Topical hydrogel plaster

    Drug: Lidocaine 5% medicated plaster

  • Placebo comparator
    Placebo plaster

    Topical hydrogel plaster

    Drug: Placebo plaster

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline of recorded average pain intensity values during the last 24 hours, averaged over the 7 days of Week 12 of the Double-blind Treatment Period.

    Time frame: Days 78-85

Secondary outcomes

  1. Mean pain intensity based on the average pain intensity during the last 24 hours, calculated over the last 4 weeks and 12 weeks of the Double blind Treatment Period.

    Time frame: up to 12 weeks

  2. Mean pain intensity based on the current pain intensity before plaster removal, calculated over the last 7 days, 4 weeks, and 12 weeks of the Double blind Treatment Period.

    Time frame: up to 12 weeks

  3. Weekly mean pain intensity before plaster removal based on the average pain intensity during the last 24 hours.

    Time frame: up to 12 weeks

  4. Weekly mean pain intensity before plaster removal based on current pain intensity before plaster removal.

    Time frame: up to 12 weeks

  5. Final score of the painDETECT Pain Questionnaire during the Double blind Treatment Period.

    Time frame: Day 85

  6. Pain intensity from mechanical dynamic allodynia (brush) testing.

    Time frame: Day 85

  7. Anxiety and depression scores of HADS.

    Time frame: Day 85

  8. The weighted Health Status Index of quality of life by means of EQ 5D.

    Time frame: Day 85

  9. Total score in quality of sleep using CPSI.

    Time frame: Day 85

  10. Mean pain intensity change from baseline based on the average pain intensity during the last 24 hours, calculated over the last 4 weeks and 12 weeks of the Double blind Treatment Period.

    Time frame: up to 12 weeks

  11. Mean pain intensity change from baseline based on the current pain intensity before plaster removal, calculated over the last 7 days, 4 weeks, and 12 weeks of the Double blind Treatment Period.

    Time frame: up to 12 weeks

  12. Weekly mean pain intensity change from baseline before plaster removal based on the average pain intensity during the last 24 hours.

    Time frame: up to 12 weeks

  13. Weekly mean pain intensity change from baseline before plaster removal based on current pain intensity before plaster removal.

    Time frame: up to 12 weeks

  14. Change from baseline in the total score of the painDETECT Pain Questionnaire during the Double blind Treatment Period.

    Time frame: Day 85

  15. Change from baseline in pain intensity from mechanical dynamic allodynia (brush) testing.

    Time frame: Day 85

  16. Change from baseline in anxiety and depression scores of HADS.

    Time frame: Day 85

  17. Change from baseline in total score of quality of life by means of EQ 5D.

    Time frame: Day 85

  18. Change from baseline in total score in quality of sleep using CPSI.

    Time frame: Day 85

07

Study locations

42 sites
  • AUT004
    Klagenfurt, Austria
  • AUT005
    Senftenberg, Austria
  • AUT006
    Vienna, 1100, Austria
  • AUT002
    Vienna, Austria
  • AUT003
    Vienna, Austria
  • AUT001
    Wien, 1090, Austria
  • BEL001
    Gozée, Belgium
  • BEL006
    Halen, 3545, Belgium
  • BEL004
    Ham, Belgium
  • BEL007
    Lanaken, 3620, Belgium
  • BEL002
    Natoye, Belgium
  • BRA005
    Barretos, 14784-400, Brazil
  • BRA002
    Itajai, 88301-220, Brazil
  • BRA001
    Porto Alegre, 91350-200, Brazil
  • BR008
    Salvador, 40170-150, Brazil
  • BRA003
    Sao Paulo, 01246-000, Brazil
  • BRA006
    São Paulo, 01323-903, Brazil
  • BRA007
    São Paulo, 04032-060, Brazil
  • DNK005
    Copenhagen, 2400, Denmark
  • DNK004
    Glostrup, 2600, Denmark
  • DNK001
    Odense, Denmark
  • FRA004
    Amiens, France
  • FRA002
    Bordeaux, France
  • FRA001
    Boulogne Billancourt, France
  • FRA003
    Le Chesnay, France
  • FRA005
    Lille, France
  • FRA010
    Montauban, France
  • FRA006
    Nantes, 44093, France
  • FRA009
    Paris, 75004, France
  • FRA008
    Saint-Priest en Jarez, 42270, France
  • FR007
    Toulouse, 31059, France
  • ITA004
    Firenze, Italy
  • ITA003
    Napoli, Italy
  • ITA001
    Rome, Italy
  • ESP001
    Barcelona, Spain
  • ESP002
    Barcelona, Spain
  • ESP006
    Madrid, 28041, Spain
  • ESP005
    Madrid, Spain
  • GBR003
    Cardiff, CF14 4XW, United Kingdom
  • GBR001
    Glasgow, G12 0YN, United Kingdom
  • GBR004
    Liverpool, L9 7LJ, United Kingdom
  • GBR002
    Manchester, M23 9LT, United Kingdom
08

References and documents

Publications

  • Palladini M, Boesl I, Koenig S, Buchheister B, Attal N. Lidocaine medicated plaster, an additional potential treatment option for localized post-surgical neuropathic pain: efficacy and safety results of a randomized, placebo-controlled trial. Curr Med Res Opin. 2019 May;35(5):757-766. doi: 10.1080/03007995.2019.1565709. Epub 2019 Jan 21. PubMed 30614286 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2012
First posted
Dec 19, 2012
Start
Oct 2012
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Last update
Jul 6, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01752322
Lead sponsor
Grünenthal GmbH
Responsible party
Sponsor
First posted
Dec 19, 2012
Start date
Oct 2012
Primary completion
Jun 2016
Completion
Jun 2016
Last update
Jul 6, 2016

Study contacts

Study Director
study director · Grünenthal GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion